CHE
Chemed Corp Health Care Services-Home Health Care Services Russell 3000
$534.72Close
$20.1BMarket cap
$367.60 – $551.9952-week range
Jan 28, 2027Next report · estimated
Highlights
Strengths
- Near its high 3% below its 52-week high
- Earnings growing EPS +22% year on year
Cautions
- Trend not confirmed 7 of 8 conditions · RS under 70
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
3%
1wk
up 4.2%
price change
1mo
up 5.9%
price change
12-month return
up 18%
market up 11% ·
its own up 5%
F-score
6 / 9
Mixed
Altman Z″
9.65
Low risk
P/E
75790.9×
price / earnings
PEG
—
P/E / EPS growth
P/B
20.5×
price / book
Earnings yield
up 1.7%
EBIT / enterprise value
Cheaper than
24%
of the market · expensive
Revenue growth
up 65%
year on year
EPS growth
up 22%
latest quarter · -21 pts
Sales growth
—
latest quarter
ROE
0%
return on equity
Free cash margin
up 13%
$325.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-0.2×
net cash
Interest cover
193.3×EBIT / interest
Piotroski tests
- profitability slipped from last year
- short-term liquidity weakened
- issued more shares
- profitable on its assets
- generating cash from operations
- profits backed by cash
- reduced long-term debt
- gross margin widened
- assets working harder
Repair signals
- Gross margin -3.0% → 32.5%
Trade setup
ATR%
2.8%
$15.10 a day · 2×ATR $504.51
RS
69 / 99
vs the universe
Trend
7 / 8
RS under 70
Relative volume
1.2×
vs 50-day average
Up/down volume
0.83
50 sessions
Implied move
—
no scheduled report
Trend template · 7 of 8
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Oct 27, 2026
Results reaction
Oct 27, 2026+3% vs market2 sessions after results
Financials
- Gross 33%
- Net 0%
- Free cash 13%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.3B | $1.3B | $1.2B | $1.3B | $1.5B | $2.5B |
| Gross margin | -3% | -9% | -14% | -11% | -3% | 33% |
| Operating income | $389.7M | $343.0M | $343.5M | $340.6M | $366.5M | $338.2M |
| Net income | $319.5M | $268,550 | $249,624 | $272,509 | $301,999 | $265,238 |
| Net margin | 24% | 0% | 0% | 0% | 0% | 0% |
| Earnings per share | $19.48 | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 |
| Free cash flow | $430.5M | $249.9M | $252.6M | $273.4M | $368.0M | $325.5M |
| Free cash margin | 32% | 20% | 21% | 21% | 24% | 13% |
| Cash | $162.7M | $32.9M | $74.1M | $264.0M | $178.3M | $74.5M |
| Long-term debt | — | $185.0M | $92.5M | — | — | — |
| Shareholders' equity | $901.2M | $623.3M | $798.7M | $1.1B | $1.1B | $979.4M |
| Shares outstanding | 36.26m | 36.51m | 36.80m | 37.18m | 37.42m | 37.59m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Jul 31, 2026 | Quarterly ↗ | Jun 30, 2026 | 31d |
| Apr 28, 2026 | Quarterly ↗ | Mar 31, 2026 | 28d |
| Feb 27, 2026 | Annual ↗ | Dec 31, 2025 | 58d |
| Oct 31, 2025 | Quarterly ↗ | Sep 30, 2025 | 31d |
| Jul 31, 2025 | Quarterly ↗ | Jun 30, 2025 | 31d |
| Apr 28, 2025 | Quarterly ↗ | Mar 31, 2025 | 28d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 1, 2024 | Quarterly ↗ | Sep 30, 2024 | 32d |
| Jul 26, 2024 | Quarterly ↗ | Jun 30, 2024 | 26d |
| Apr 29, 2024 | Quarterly ↗ | Mar 31, 2024 | 29d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 27, 2026 | Results ↗ |
| Jul 28, 2026 | Results ↗ |
| May 19, 2026 | Shareholder vote ↗ |
| Apr 23, 2026 | Results ↗ |
| Apr 13, 2026 | Material agreement · New obligation ↗ |
| Feb 25, 2026 | Results ↗ |
| Oct 28, 2025 | Results ↗ |
| Jul 29, 2025 | Results · Director or officer change ↗ |
| Jun 27, 2025 | Regulation FD ↗ |
| May 20, 2025 | Shareholder vote ↗ |
| Apr 23, 2025 | Results ↗ |
| Feb 26, 2025 | Results ↗ |